V608112022 Afrigen South African hub Biovac Institute Pasteur Tunis Tunisia BioGeneric Pharma Egypt TBD Kenya Institute Pasteur Dakar Senegal Biovaccines Nigeria ID: 1000147
Download Presentation The PPT/PDF document "Vaccines' Investment Mapping" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Vaccines' Investment MappingV6.08.11.2022
2. Afrigen South African hub+BiovacInstitute Pasteur Tunis - TunisiaBioGeneric Pharma – EgyptTBD - KenyaInstitute Pasteur Dakar - SenegalBiovaccines -Nigeriaend-to-endSpokes & Current industrial initiatives for Covid-19 vaccines in AfricaFill&FinishmRNA plans to 3rd parties mRNA spokesAlgeriaMoroccoGhanaUgandaRwanda Source: CHAI and UNICEFBotswanamRNA vaccine production CompaniesKenyaModernaModerna and Kenya signed a MoU to build mRNA facilityRwanda Senegal, South AfricaBioNTech BioNTech announced a plan to develop the capacity to produce upcoming mRNA-based vaccinesGhanaBioNTechBioNTech to establish manufacturing plants for fill, finish and packagingOther Industrial PartnershipsAlgeriaSaidal & Sinovac200M capacity, started in 2021, then move up the value chain Saidal & GamaleyaSputnik V starting Sept 2021 ($40M capacity)Sothema & Sinopharm $60M capacitySouth AfricaAspen & J&J F&F started in 2021. 2022 plan to manufacture under Aspen’s brand nameNantSA & Immunity BioTo set up a new plant to produce vaccines Rubic Consortium & Dyadic & WITS to establish a new plantBiovac & Pfizer started a tech transfer in 2021 for AU member states EgyptEva Pharma EgyVax currently under Ph 1Vacsera & Sinovac Produced ~30M doses of Sinovac vaccineMinipharma & GamaleyaTo produce 40M doses per yearBotswanaNantWorks to establish a new plant and to produce Corbevax by 2026
3. Financial &Technical contributions to African vaccine local production outside of the mRNA Tech Transfer HubInstitutionContent of the supportAFDGranted €1.8M to IPD for a feasibility studyAfreximbankTo support infrastructural facilities and initiate vaccine production in Ogun State, Nigeria for €180M Belgium€4.5M for NRA strengthening in Senegal and €0,5M to RwandaGermany BMZ (KfW) granted €20M to IPD’s MADIBA project and €1M to develop vaccine production capacity BMZ (GIZ) committed €5M to Ghana to advance local manufacturing + 0.18M +€2.7M co-financing from EU to strengthen the FDA BMZ (GIZ) committed €11.7M for establishing a local vaccine in Rwanda and €24M to support EAC Centre of Excellence for vaccine DEG support to Aspen with €144M (J&J vaccine) €51M to South Africa to support vaccination campaigns and the development of a vaccine supply chain (incl. regulatory strengthening) €10M to support ACDC and promote regulatory framework €250M promotional loan to Afreximbank + €12.2M to the prep4vac project InstitutionContent of the supportFCDOFCDO supported the business case development and feasibility assessment for Aspen and IPD IFC coalition IPD €13M grant for MADIBA project Rwanda and Morocco to conduct diagnostic and feasibility studies Biovac to raise €136M Aspen contracted €644M loanTeam Europe & EU IPD received €6.7M to support the MADIBA project Granted €3.1M to RwandaUS Gov US DFC granted €2.9M to IPD to support the MADIBA project Aspen received €181M to produce J&J vaccine for the African continentWorldBankAttributed Granted €27M to Biovaccines for vaccine manufacturing plant
4. Spokes & current industrial initiatives for Covid-19 vaccines in Latin America Source: CHAI and UNICEFmRNA spokesmRNA plans to 3rd parties Fill&FinishEnd to EndArgentina - Sinergium Biotech Brazil – Bio-ManguinhoVenezuelaPeruMexicoCubamRNA vaccine production CompaniesBrazilHDT Bio & SENAI CIMATEC HDT Bio granted to SENAI CIMATEC a non-exclusive license to produce its RNA vaccine Eurofarma & BioNtech to produce 100M doses Other Industrial PartnershipsArgentinaRichmond Lab & Gamaleya Research Instituteto produce SputnikmAbxience & AstraZenecamAbxience to produce AstraZeneca’s drug substance to be FF in Mexico Sinergium & Sinopharm to produce 1M doses /week BrazilFiocruz & AstraZeneca for 100.4M doses capacityBiomm & CanSino to distribute the vaccine in BrazilUnião Química & Gamaleyato set up FF capacityInstituto Butantan & Sinovac to produce 1M doses CubaBioCubaFarmadeveloped Abdala and Soberana 2 vaccineMexicoBirmex & GamaleyaBirmex & AstraZenecaPeruPlans to build a plant in 2023 to produce Sputnik V and other vaccinesVenezuela Espromed-Bio & Center for Genetic Engineering and BiotechnologyEspromed-Bio to produce 4M doses from the Center for Genetic Engineering and Biotechnology
5. Current industrial initiatives for Covid-19 vaccines in Asia Source: CHAI and UNICEFPakistan - National Institute of HealthVietnam - PolyvacBangladesh – Incepta Indonesia - BiofarmaMalaysiaSri LankaPhilippinesThailandmRNA spokesmRNA plans to 3rd parties Fill&FinishEnd to EndmRNA vaccine production Bangladesh Globe Biotech to develop its own mRNA vaccines. Under Ph1ThailandBionet consortium composed of Pennsylvania, North Carolina, California-Davis, Chulalongkorn, IVI. Currently under Ph 2 CTVietnamVinbiocare & ArcturusOther Industrial PartnershipsBangladesh Incepta to produce Corbevax Incepta & Sinopharme MoU to produce 5M dosesIndonesiaBio Farma & Children’s Hospitalto produce Texas Children’s Hospital’ vaccineBio Farma & SinovacMalaysiaPharmaniaga & Sinovac to distribute then produce 14M dosesSolution Biologic & CansinoPhilippinesGlovax Biotech & Eubiologics to produce 40M dosesSri LankaState Pharmaceutical Corporation & Sinovacto produce 9M doses ThailandSiam Bioscience & AstraZenecaVietnamIVACstops Ph 3 CT of its COVIVAC due to volunteer shortagesIVAC & CIGBto produce Cuban Abdala vaccineNanogento develop a recombinant vaccine that is still under Ph 3 trialVabiotech & GamaleyaVabiotech& Shionogi AIC & Shionogi Polyvac & Gamaleya
6. Current industrial initiatives for Covid-19 vaccines in India Source: CHAI and UNICEFmRNA spokesmRNA plans to 3rd parties Fill&FinishEnd to End Drug substance mRNA vaccine production CompaniesGennovaGennovaGennova is developing mRNA vaccineOther Industrial PartnershipsBiological E Biological E & Texas Children’s HospitalBiological E & J&J Biological E & J&J to collaborate to produce 600M doses/year Serum Institute of India SII & NovavaxSII & Gamaleya Research InstituteSII & AstraZenecaBharat Biotech Bharat BiotechTo develop an inactivated vaccineBharat Biotech & Haffkine Bharat Biotech to licence HaffkineBharat Biotech & Indian Immunologicals Bharat Biotech to licence Indian Immunologicals Bharat Biotech & Hester BiosciencesBharat Biotech & Hester Biosciences to sign a CDMOPanaceaCEPI support the development of multi-epitope, nanoparticle-based vaccine candidatesGamaleya Gamaleya & Gland Pharma To produce 252M dosesGamaleya & Hetero BiopharmaGamaleya & Morepen LaboratoriesGamaleya & Panacea BiotecCollaboration discharged Gamaleya & Stelis Pharma To produce 900M dosesGamaleya & Virchow BiotechGamaleya & Wockhardt
7. Current industrial initiatives for Covid-19 vaccines in ChinaSource: CHAI and UNICEFmRNA spokesmRNA plans to 3rd parties Fill&FinishEnd to End mRNA vaccine developmentCSPC ZhongQiUnder Ph 2 CT Fosun Pharma & BioNtech China yet to approve BioNtech vaccine WalvaxGot approval in IndonesiaEverest Medicines & ProvidenceLicense agreement to produce Covid-19 and other vaccines Stemirna Therapeutics To develop then produce up to 400M dosesSinopharmTo wait approval to initiate Ph1 CTCR Pharma & Everest MedicinesTo establish the company “mRNA&Co” focused on vaccines discoveryCanSinoUnder Ph 3 CTSuzhou Abogen Biosciences Under Ph 1 CTAIM Vaccine Under Ph 3 CTWuhan Recogen Biotechnology Under Ph 1 CTOther Industrial Partnerships & productionAnhui Zhifei LongcomUnder Ph 3 CT CanSinoSinovacSinopharmInstitute of Medical Biology of the Chinese Academy of Medical SciencesTo produce between 500M and 1 billions dosesShanghai Zerun Bio & WalvaxCEPI support to develop COVID-19 multi-variant vaccinePoly Pharm & CelsionTo produce DNA based vaccine Advaccine & Inovio To produce DNA based vaccine BioKangtai & AztraZeneca Rhodiola Bacterin & Gamaleya Shenzhen Yuanxing Gene-tech & Gamaleya To produce 60M dosesTopRidge Pharma & Gamaleya Hualan Biological Bacterin & Gamaleya To produce 100M doses